Welcome to our dedicated page for GeneDx Holdings news (Ticker: WGS), a resource for investors and traders seeking the latest updates and insights on GeneDx Holdings stock.
GeneDx Holdings Corp. (Nasdaq: WGS), commonly referred to as GeneDx, regularly issues news focused on rare disease genomics, clinical impact, and corporate developments. The company describes itself as the global leader in rare disease diagnosis and a pioneer in genomic medicine, emphasizing the role of exome and genome sequencing and its GeneDx Infinity dataset in transforming care.
News updates from GeneDx often highlight financial results and guidance, including revenue trends, exome and genome test volumes, and margin profiles, alongside commentary on how these metrics relate to the company’s growth in genomic testing. Earnings releases may be accompanied by details on conference calls and investor presentations.
GeneDx also publishes frequent announcements on scientific and clinical milestones. These include peer‑reviewed publications, participation in large genomic newborn screening programs such as GUARDIAN and BEACONS, and recognition of its research by major medical journals. The company’s news flow covers conference presentations, advances in rapid genome sequencing, and developments in long‑read sequencing and gene–disease discovery.
Additional news items describe new test offerings like GenomeDx Prenatal, leadership appointments in medical and business roles, and partnerships such as the collaboration with Komodo Health to link GeneDx Infinity with real‑world healthcare data. For readers following WGS, this news page provides a centralized view of GeneDx’s financial disclosures, research output, clinical initiatives, and strategic collaborations in rare disease genomics.
GeneDx (NASDAQ: WGS) reported strong Q2 2025 financial results, with revenue reaching $102.7 million, marking a 49% year-over-year increase. The company's core exome and genome test revenue grew 69% year-over-year to $85.9 million, with test volume increasing 28% to 23,102 tests.
Key financial metrics include an expanded adjusted gross margin of 71% and an adjusted net income of $15.0 million, marking the fourth consecutive profitable quarter. The company has raised its full-year 2025 guidance to $400-415 million in revenue.
Strategic developments include the acquisition of Fabric Genomics and a significant endorsement from the American Academy of Pediatrics, now recommending exome and genome sequencing as first-tier tests for children with developmental delays. The company has also expanded Medicaid coverage to 35 states for pediatric outpatient testing.
GeneDx (Nasdaq: WGS), a genomic insights company, has scheduled its Q2 2025 financial results announcement for Tuesday, July 29, 2025, before market opening. The company will host a conference call at 8:30 a.m. Eastern Time to discuss the quarter's financial and operating performance.
Investors must register online to participate in the conference call. Both live and archived versions of the webcast will be accessible through the "Events" section on GeneDx's investor relations website.
GeneDx (Nasdaq: WGS) announced significant findings from the SeqFirst study, conducted with Seattle Children's, demonstrating the effectiveness of rapid genomic testing in non-critical pediatric inpatients. The study revealed that implementing rapid exome sequencing (rES) and rapid genome sequencing (rGS) as first-tier tests dramatically reduced diagnosis time from 289 days to just 13 days.
The research showed a high diagnostic yield exceeding 40%, comparable to critical care settings. Key findings include a 91% rate of genetic testing recommendations from providers and a threefold increase in precise genetic diagnoses from initial encounters when using rES/rGS as first-line testing.
GeneDx (WGS), a genomic insights company, announced its participation in two upcoming investor conferences in June 2025. The company will present at the Jefferies Global Healthcare Conference in New York City on June 4 at 9:55 a.m. ET and the Goldman Sachs 46th Annual Global Healthcare Conference in Miami Beach on June 9 at 4:00 p.m. ET.
Both presentations will be available via live and archived webcasts on the company's investor relations website. GeneDx specializes in rare disease diagnostics through exome and genome testing, focusing on delivering personalized healthcare solutions and advancing drug discovery.
GeneDx (WGS) has published an article in the American Journal of Medical Genetics highlighting its vision for implementing AI in genomic diagnostics. The company aims to leverage its comprehensive genomic and phenotypic dataset to enhance genetic disease diagnosis through AI applications. The publication demonstrates GeneDx's strategy to address the growing demand for genetic testing as costs decrease and testing becomes standard care.
Key developments include AI systems for extracting phenotypic data and prioritizing genetic variants, working alongside genetics professionals. Following the recent acquisition of Fabric Genomics, GeneDx is positioning itself to enable decentralized testing with centralized intelligence, potentially setting new standards in genomic medicine globally.
GeneDx (WGS) has completed its acquisition of Fabric Genomics, a leader in AI-powered genomic interpretation. The strategic combination creates an integrated ecosystem for genomic diagnostics, offering both centralized and decentralized testing solutions powered by GeneDx's clinical expertise and Fabric's AI technology. Fabric Genomics will operate as an independent subsidiary of GeneDx.
The acquisition accelerates key growth opportunities including: faster diagnosis for critically ill newborns through NICU genomic testing, support for global newborn screening programs, international commercial expansion across EMEA, APAC, and LATAM regions, and new recurring revenue streams through Fabric's interpretation-as-a-service model.
GeneDx reported strong Q1 2025 financial results, with total revenues reaching $87.1 million, marking a 42% year-over-year increase. The company's core exome and genome test revenue grew impressively by 62% to $71.4 million, with test volume up 24% to 20,562 tests.
Key highlights include achieving an adjusted gross margin of 69% and adjusted net income of $7.7 million, compared to a loss in Q1 2024. The company announced plans to acquire Fabric Genomics and launched new initiatives including ultraRapid Whole Genome Sequencing and Epic Aura integration.
GeneDx raised its 2025 revenue guidance to $360-375 million and maintains its target of at least 30% growth in exome/genome volume and revenue. The company expanded its coverage to 33 states for pediatric outpatient testing and 14 states for NICU rapid genome sequencing, positioning itself for continued growth in genomic medicine.
GeneDx (WGS) has announced plans to acquire Fabric Genomics, an AI-powered genomic interpretation pioneer, in a deal worth up to $51 million. The acquisition combines GeneDx's extensive rare disease data asset with Fabric Genomics' AI platform to enable decentralized testing with centralized intelligence.
The transaction, expected to close in Q2 2025, includes $33 million in cash upon closing, with additional $18 million tied to milestone achievements. This strategic move will expand GeneDx's addressable market through multiple revenue streams:
- NICU Genomic Testing: Targeting the underserved market where less than 5% of 400,000 annual NICU admissions receive genetic testing
- Genomic Newborn Screening: Addressing a market of 3.7M U.S. births and 130M globally
- Global Commercial Expansion: Enabling local sequencing with centralized AI interpretation
- Platform Economics: Leveraging 750,000+ exomes/genomes dataset for AI development and clinical decision support